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Although several studies are available on the in vitro inhibitory activities of type I interferon (IFN) on HIV-1 replication, the
role of these cytokines in the pathogenesis of AIDS is still matter of conjecture. Both beneficial and adverse effects have
been envisaged and considered as a possible rationale for the development of either IFN or anti-IFN therapies in
HIV-1-infected patients. In the present study, we have evaluated the efficacy of human type I IFN on HIV-1 infection and
virus-induced depletion of human CD4 T cells in two models established in SCID mice. In SCID mice transplanted with human
U937 cells (U937-SCID mouse model), continuous treatment with type I consensus IFN (CIFN) resulted in a total suppression
of HIV-1 infection. This inhibitory effect was superior to that obtained after AZT treatments. Results from an ensemble of
experiments in SCID mice transplanted with either control or genetically modified human U937 cells transduced with a
Tat-inducible IFN-a gene (LTR-IFN-A2 U937) indicated that low levels of IFN-a, produced locally as a result of virus infection,
were extremely effective in inhibiting acute HIV infection and virus replication. Of interest, LTR-IFN-A2 U937 cells conferred
a strong anti-HIV-1 protection to coinjected bystander U937 cells. Notably, experiments with SCID mice reconstituted with
human PBL (hu-PBL-SCID mouse model) showed that treatment with CIFN inhibited HIV-1 replication more effectively than
AZT treatment. Remarkably, treatment with CIFN resulted in a clear-cut protection from the virus-induced depletion of human
CD4 T cells, which was also associated with the generation of an antibody response toward HIV-1 antigens in 50% of the
virus-injected xenografts. These results suggest that type I IFN efficiently preserves human CD41 cells from virus-induced
damage in hu-PBL-SCID mice, not only by inducing an antiviral state in target cells but also by stimulating anti-HIV-1 human
immune responses in vivo. © 1999 Academic Press
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Several groups have reported that type I interferon
IFN) inhibits HIV-1 replication in human cells cultivated
n vitro (Bednarik et al., 1989; Dolei et al., 1986; Gendel-
an et al., 1990; Hartshorn et al., 1987; Kornbluth et al.,
989; Poli et al., 1989; Shirazi and Pitha, 1992). These
tudies have pointed out the existence of multiple mech-
nisms by which IFN can affect the HIV infectious cycle,
epending on the target cells and the timing of IFN
ddition and virus infection. In the light of the anti-HIV
ctivities observed in certain in vitro cell systems, some
linical trials have been performed with type I IFN (es-
ecially a), alone or in combination with anti-HIV drugs,
n infected patients (Fernandez-Cruz et al., 1995; Frissen
t al., 1994; Kovacs et al., 1996; Lane et al., 1988, 1990;
ka et al., 1989; Rivero et al., 1994, 1997; Skillman et al.,
996). Although a beneficial effect was observed in some
f these trials, especially when patients were treated
xtensively at early stages of HIV disease (Lane et al.,
990; Rivero et al., 1997; Skillman et al., 1996), there is no
1 To whom correspondence and reprint requests should be ad-
oressed. Fax: 396.49387184. E-mail: belard@virus1.net.iss.it.
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78eneral agreement on the possible advantage of a clin-
cal use of IFN. Thus, the role of this cytokine in the
athogenesis of HIV-1 infection is still matter of conjec-
ure. In particular, the fact that IFN (commonly termed
cid labile IFN-a) is generally present in the serum of
IV-1-infected patients at late stages of the disease (Lau
nd Williams, 1990) has led to the suggestion that this
ytokine can play a role in the progression to AIDS.
oreover, some authors have suggested that type I IFN
especially IFN-a) is an important cofactor in HIV-1 dis-
ase, which is directly involved in the suppression of
D4 T cell functions (Fall et al., 1995; Gringeri et al., 1994,
995; Lachgar and Bizzini, 1994). This assumption is
ostly based on the observation that IFN-a can inhibit,
nder certain in vitro conditions, the proliferation of ac-
ivated T cells and that HIV-1 proteins (i.e., tat) can
nduce the production of this cytokine (Zagury et al.,
998). Recently, clinical applications aimed at neutraliz-
ng the endogenously produced IFN-a in HIV-1-infected
atients have begun (Gringeri et al., 1994, 1995). Notably,
owever, recent studies have shown that the transduc-
ion of the IFN-b gene into human PBL results not only in
nhibition of HIV replication but also in an enhancement
f the development of a potentially protective T cell
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79ANTI-HIV-1 EFFECTS OF TYPE I IFN IN SCID MOUSE MODELSmmunity (Vieillard et al., 1997). Since both IFN-a and
FN-b bind to the same receptor and share many biolog-
cal properties, these results might suggest that, in gen-
ral, type I IFN can play beneficial, rather than adverse,
ffects on T cell functions in the course of HIV-1 infec-
ion. Thus, contrasting views may coexist at this stage of
ur knowledge on the role of type I IFN in the pathogen-
sis of HIV-1 infection. In this regard, studies on animal
odels would be helpful for the evaluation of the in vivo
ole of type I IFN in HIV-1 infection and virus-induced
epletion of human CD4 T cells.
In the present study, we have evaluated the efficacy of
uman type I IFN in affecting HIV-1 infection in different
odels of SCID mice transplanted with human cells.
esults from an ensemble of experiments carried out in
CID mice transplanted with parental or genetically
odified human cell lines show that type I IFN effectively
revents acute HIV infection and inhibits HIV replication,
hen it is produced locally at the infection site. Further-
ore, data of experiments with chimeric models of SCID
ice reconstituted with human PBL (Mosier et al., 1991)
ave shown not only an impressive type I consensus IFN
CIFN)-induced inhibition of HIV infection (superior to
hat obtained with AZT treatments) but also a clear-cut
rotection from the virus-induced depletion of human
D4 T cells. Altogether, these results indicate that in vivo
ype I IFN does not contribute to HIV-induced depletion
f CD4 T cells, but it effectively counteracts the delete-
FIG. 1. Inhibition of HIV infection in SCID mice transplanted with U937
f either CIFN or AZT on tumor growth (A) and p24 antigenemia (B) in
ere injected at the same time with 2 3 107 U937 cells together with
IFN (105 U/0.2 ml/mouse, sc; daily, from day 21 to day 125); (E) SCID
C) HIV-1 DNA PCR analysis of U937 tumor tissues dissected at day
umber/2 3 105 tumor U937 cells). DNA was extracted by standard proc
f the assay was 10 proviral DNA copies, as tested by amplifying DNA
CID mouse cell DNA, as described elsewhere (Lapenta et al., 1997;ious effects of virus infection, by directly acting on the wuman target cells and, possibly, by enhancing human
nti-HIV-1 immune responses in the reconstituted SCID
ice.
RESULTS
epeated treatments of SCID mice with exogenous
IFN completely inhibit HIV-1 infection of
ransplanted human U937 cell tumors
Coinjection of SCID mice with human U937 cells and
IV-1 results in a progressive infection of the trans-
lanted cells as revealed by the appearance of increas-
ng levels of virus antigen (p24) in the serum and HIV-1
xpression at the tumor site (Lapenta et al., 1997). Figure
B shows the kinetics of development of p24 antigen-
mia in SCID mice injected with U937 cells and HIV.
aily treatments for 25 days with 105 units of type I CIFN
tarting from the day before virus infection resulted in a
omplete suppression of the development of p24 anti-
enemia (Fig. 1B). Likewise, AZT treatment also resulted
n inhibition of p24 antigenemia (Fig. 1B). CIFN treatment
as associated with a significant delay in tumor growth
ompared to control treated and untreated mice (Fig. 1A).
s illustrated in Fig. 1C, the PCR analysis of freshly
issected U937 cells from IFN-treated mice did not re-
eal the presence of HIV-1 infection at the tumor site,
hile only a reduction in the HIV proviral copy number
fter repeated treatments with type I IFN (CIFN) or AZT. (A and B) Effect
ice transplanted sc with U937 cells infected in vivo with HIV-1. Mice
IIIB 103 TCID50). (n) Untreated SCID mice; () SCID mice treated with
treated with AZT (9 mg/ml/mouse, ip; daily, from day 21 to day 125).
er the simultaneous injection of U937 cells and HIV-1 (proviral copy
nd amplified for gag-specific sequences (Rizza et al., 1996). Sensitivity
ed from 8E5-T-cells (Folks et al., 1986), which was serially diluted into
t al., 1996). There were six mice in each group.cells a
SCID m
HIV-1 (
mice
30 aft
edure a
, preparas observed in mice treated with AZT.
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80 LAPENTA ET AL.937 cells transduced with the Tat-inducible IFN-A2
ene are strongly protected from HIV-1 infection
fter transplantation into SCID mice: Role of
irus-induced IFN-A
In the experiments described above, we had to start
njecting 105 units of CIFN 1 day before virus inocula-
ion in order to achieve total protection from HIV-1
nfection of the U937 cell transplanted SCID mice.
njection of lower doses of exogenous CIFN (104
/mouse) resulted in partial protection from HIV-1 in-
ection (data not shown). It was of interest to evaluate
he possible effects of low levels of endogenous IFN
roduced locally as a result of virus infection. To
ddress this issue, we used U937 cells containing
ntegrated HIV-1 LTR-IFNA2 hybrid plasmids (Su et al.,
995). In the present study, we used a cloned popula-
ion of cells (ULTR5-14). These cells produced low
onstitutive levels of IFNA in vitro, whose production
as significantly increased 2–3 weeks after HIV-1 in-
ection (Su et al., 1995). HIV-1 (pLN4-3) replication was
lmost completely inhibited for 25 days postinfection
Su et al., 1995). We therefore compared the extent of
IV-1 infection in LTR-IFNA2 U937 cells and control
ransduced cells when transplanted into SCID mice.
able 1 shows the results of a representative experi-
ent in which SCID mice were injected simulta-
eously with the genetically modified U937 cells and
IV-1. On days 15 and 24 after infection, all the mice
ransplanted with control U937 showed high levels of
erum p24, while no detectable or low levels of anti-
enemia were observed in mice injected with LTR-
FNA2 U937 cells and HIV-1. The evaluation of the
xtent of HIV-1 infection in freshly recovered U937
ells on day 24 after infection revealed a clear-cut
T
Effect of the Simultaneous Injection of SCID Mice with Ei
on the Development of p24 Antigenemia a
Cells injected
Mouse
No.
Serum p24 (pg
Day 15
U937 1 $16,000
2 $16,000
3 $16,000
LTR-IFN-A2 1 112
U937 2 Below detection
3 Below detection
a Five-week-old female SCID were injected sc with 107 cells together
ice in each group were tested for p24 levels. Mice were sacrificed o
esting the serum p24 levels and the level of HIV-1 infection at the tum
iameter 20 6 2 mm).
b p24 released in the culture medium from the freshly dissociated tu
c IFN released in the culture medium from freshly dissociated tumor
d Immunostaining for HIV p55/18 matrix protein of the freshly dissocnhibition of HIV-1 replication in LTR-IFNA2 U937 with nespect to control U937 cells, as shown by the capa-
ility of the cells to produce HIV in vitro and to express
iral antigens (Table 1). Figure 2 shows a typical ex-
mple of the marked difference in the number of HIV-
-positive cells observed by performing immunostain-
ng techniques with the two types of U937 cell popu-
ations. Notably, even though no IFN activity was found
n the sera of HIV-1-infected mice injected with LTR-
FNA2 U937 cells, low levels of human IFN were con-
istently detected in the 24-h supernatants of recov-
red tumor cells cultivated in vitro (Table 1). No IFN
ctivity was found in the supernatants of control U937
ells (recovered from the injected mice), which pro-
uced large amounts of HIV-1 (Table 1). These results
uggested that even low levels of IFN produced locally
fter HIV-1 infection can effectively suppress multiple
ycles of HIV-1 infection and replication.
We then undertook a set of experiments aimed at
etermining whether LTR-IFNA2 U937 cells could protect
ontrol parental U937 cells from HIV-1 infection in vivo.
s shown in Fig. 3B, LTR-IFNA2 U937 cells totally inhib-
ted the development of HIV antigenemia when coin-
ected with control U937 cells, clearly indicating that the
FN produced by LTR-IFNA2 U937 cells as a response to
IV infection can effectively suppress virus replication
ot only in these cells but also in the bystander parental
ells. In this experiment (in which a very low m.o.i. of
IV-1 was used), tumors developed in mice transplanted
ith either LTR-IFNA2 U937 cells alone or with a mixture
f LTR-IFNA2 and parental U937 cells. However, none of
he LTR-IFNA2 or the mixed LTR-IFNA2/parental U937
umors showed the presence of HIV-1, as tested by PCR
nalysis of DNA extracted from the corresponding tu-
ors (Fig. 3C) and by RT-PCR to detect HIV-1 RNA (data
R-IFN-A2 U937 or Control U937 Cells Together with HIV
Extent of HIV Infection at the Tumor Sitea
In vitro
p24b
(pg/ml)
In vitro
IFNc
(U/ml)
HIV1
cellsd (%)ay 24
80,000 $20,000 ,4 36.6
80,000 $20,000 ,4 63.3
80,000 $20,000 ,4 65.5
1,280 20,000 256 23.0
200 325 256 1.6
140 370 256 2.3
V IIIB (m.o.i. 105 TCID50) (day 0). On day 15, serum aliquots from tagged
4 and the extent of virus infection at this time point was evaluated by
. All the sacrificed mice showed comparable tumors on day 24 (mean
lls after 24 h of culture.
fter 24 h of culture.
mor cells on day 24.ABLE 1
ther LT
nd the
/ml)
D
$
$
$
with HI
n day 2
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81ANTI-HIV-1 EFFECTS OF TYPE I IFN IN SCID MOUSE MODELSFigure 4 shows the results of two representative exper-
ments in which we injected HIV-1 in SCID mice bearing
stablished U937 cell tumors. SCID mice bearing U937 cell
umors of comparable size (15 days after transplantation)
ere injected sc with HIV-1. The animals were sacrificed 2
eeks later to determine the serum p24 levels and the
resence of virus in the freshly dissociated tumor cells
ultivated in vitro for 24 h. As shown in Fig. 4, a marked
nhibition of HIV-1 antigenemia was observed in mice trans-
lanted with LTR-IFNA2 U937 cells when compared to the
nimals inoculated with control U937 cells. This suppres-
ion in p24 levels was consistent with the inhibition of HIV
roduction observed in the LTR-IFNA2 U937 tumor cells
FIG. 2. Detection of HIV-1 p55/18-expressing cells in freshly disse
ransduced cells and infected with HIV-1. (A) Tumors from mice transpl
ith LTR-IFNA2 U937 cells. Magnification, 6503.ultured for 24 h in vitro. wrotection from HIV-1 infection and CD4 T cell
epletion in SCID mice reconstituted with human PBL
The use of the hu-PBL-SCID mouse model allows one
o analyze in vivo not only HIV-1 infection but also the
IV-mediated immune dysfunction and particularly virus-
nduced CD4 T cell depletion (Mosier et al., 1991, 1993;
izza et al., 1996). We have therefore evaluated the ef-
ects of CIFN treatment on HIV-1 infection in the hu-PBL-
CID model and compared it to the response obtained
fter administration of a reference anti-HIV drug (AZT).
he hu-PBL-SCID mice were treated daily with either
ype I CIFN or AZT (starting 13 days after reconstitution
mors from SCID mice transplanted with LTR-IFNA2 U937 or control
ith control transduced U937 cells. (B) Tumors from mice transplantedcted tu
anted with human cells) and infected with HIV-1 on day 14.
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82 LAPENTA ET AL.nimals were sacrificed 2 weeks later and the extent of
IV-1 infection and CD4 depletion was determined. As
hown in Figs. 5A and 5B, treatment with CIFN resulted
n a total suppression of HIV replication measured by the
IV-1 plasma RNA copy number and by the levels of HIV
24 in the peritoneal washings. AZT also suppressed
IV-1 replication, but the inhibition was lower than in
IFN-treated animals (Figs. 5A and 5B). Notably, the
FIG. 3. Protection from HIV infection in SCID mice transplanted wit
rowth (A) and p24 antigenemia (B) in SCID mice transplanted sc with
07 LTR-IFNA2 U937 cells together with the same number of control U
CID mice. There were six mice in each group. (C) HIV-1 DNA PCR ana
bove. DNA was extracted (at day 30 after the injection with U937 cells
Rizza et al., 1996). The PCR results for three representative mice pe
repared from 8E5-T-cells (Folks et al., 1986), which was serially diluted
t al., 1996).ymph nodes and spleen from all the hu-PBL-SCID mice anfected with HIV-1 and treated with CIFN showed a high
evel of reconstitution with human cells (as evaluated by
CR for HLA-DQa) and no presence of viral infection (as
evealed by PCR analysis for HIV DNA) (data not shown).
f interest, anti-HIV-1 antibodies were detected in the
erum of virus-infected hu-PBL-SCID mice treated with
IFN (Fig. 5C).
Figure 6 shows the percentages of human CD41
FNa2A U937 cells together with control U937 cells. (A and B) Tumor
37 cells (2 3 107 cells), (h) LTR-IFNA2 U937 cells (2 3 107 cells), ()
ls. Cells were mixed with HIV-1 (IIIB, 103 TCID50), before injection into
U937 tumors from SCID mice inoculated with U937 cells as described
V-1) by standard procedures and amplified for gag-specific sequences
are shown. Sensitivity of the assay was tested by amplifying DNA,
ID mouse cell DNA, as described elsewhere (Lapenta et al., 1997; Rizzah LTR-I
: (n) U9
937 cel
lysis of
and HI
r group
into SCnd CD81 T cells found in the different groups of
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83ANTI-HIV-1 EFFECTS OF TYPE I IFN IN SCID MOUSE MODELSu-PBL-SCID mice in two representative experiments.
he infection of control hu-PBL-SCID mice with HIV
esulted in a clear-cut depletion of human CD4 T cells.
n contrast, HIV-infected mice treated with CIFN
howed high levels of human CD4 T cells, which were
omparable or even higher than in control uninfected
nimals (Fig. 6, experiments 1 and 2, respectively).
ZT also protected hu-PBL-SCID mice from the HIV-1-
nduced depletion of human CD4 T cells, but this
FIG. 4. Effects of HIV-1 infection in SCID mice bearing either contr
ix-week-old female SCID mice were injected sc with 2 3 107 U937 c
nder Materials and Methods. On day 15, mice bearing comparable sc
CID50) intratumorally. Two weeks later, the mice were sacrificed and
he collected serum; (ii) the levels of in vitro p24 production by the U937
ere five mice in each group. (h) Mice injected with control U937 cel
FIG. 5. Suppression of HIV-1 infection by CIFN in hu-PBL-SCID mice:
ere reconstituted with human PBL as described under Materials and
/mouse, sc) or AZT (9 mg/mouse, ip). Hu-PBL-SCID mice were infecte
fter HIV-1 infection. HIV-1 RNA copy number in the plasma p24 lev
etermined as described under Materials and Methods. Values from thrn two other experiments.rotective effect was always lower than that observed
n animals treated with CIFN. Remarkably, 50% of the
IV-1-injected hu-PBL-SCID mice treated with IFN
howed the presence of anti-HIV-1 human antibodies
IgG), while no specific antibodies were detected in
he other groups of mice (data not shown).
As shown in Fig. 7, protection from virus-induced
D4 T cell depletion was also observed when CIFN
reatment was discontinued on day 7 after HIV infec-
TR-IFNA2 U937 cell tumors on the development of p24 antigenemia.
indicated. Mice were treated with anti-granulocyte mAb as described
s (mean tumor diameter 8 6 2 mm) were injected with HIV-1 IIIB (106
nt of HIV-1 infection was evaluated by testing: (i) p24 antigenemia in
issociated from the sc tumors and maintained in culture for 24 h. There
Mice injected with LTR-IFN-A2 U937 cells.
rison with the effects induced by AZT. Five-week-old female SCID mice
ds. Starting on day 13, mice were daily treated with either CIFN (105
y 14 with HIV-1 SF-162 (103 TCID50, ip). Mice were sacrificed 2 weeks
the peritoneal washings and anti-HIV-1 antibodies in the sera were
vidual mice from each group are shown. Similar results were obtainedol or L
ells as
tumor
the exte
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84 LAPENTA ET AL.ion. Notably, HIV-infected hu-PBL-SCID mice treated
ith CIFN exhibited much higher levels of IgM than
ontrol mice and a direct correlation was generally
bserved between the percentages of human CD4 T
ells and levels of human IgM in the sera of the
njected mice. Of interest, in this experiment the sera
f two of four mice infected with HIV-1 and treated with
IFN showed the presence of specific antibodies to
IV-1, while none of control mice developed anti-HIV-1
ntibodies (data not shown).
FIG. 6. Persistence of high levels of human CD4 T cells in hu-PBL-S
he effects of AZT. Hu-PBL-SCID mice were treated daily with either CI
. Two weeks after infection, the mice were sacrificed and the percenta
ere determined as described under Materials and Methods. There we
re shown.
FIG. 7. Persistence of high levels of human CD4 T cells and human
gM in HIV-1-infected hu-PBL-SCID mice in which the IFN treatment
as discontinued. Hu-PBL-SCID mice were treated daily sc with 0.2 ml
f either CIFN (105 U/mouse) or saline, from day 8 to day 16. Mice were
njected with HIV-1 (SF162, 103 TCID50, ip) on day 9. The animals were
acrificed on day 35. The percentages of human CD41T cells and the
evels of human IgM were determined in the peritoneal washings of
tndividual mice. There were four mice in each group.DISCUSSION
The results reported in this article demonstrate that
ype I IFN can act as a powerful suppressor of HIV-1
eplication in human cells transplanted into SCID mice
nd can efficiently preserve human CD4 T cells from the
eleterious effects induced by virus infection. In both
odels used in this study (U937-SCID and hu-PBL-SCID
ouse models), the protective effects against HIV-1 in-
ection obtained after IFN treatment were more marked
han those observed after AZT administration. We have
reviously shown that cells permanently transfected with
Tat-inducible IFNA2 expression plasmid are not per-
issive to HIV-1 replication (Bednarik et al., 1989; Su et
l., 1995). The use of genetically modified LTR-IFNA2
937 cells in SCID mice allowed us to evaluate in vivo
he efficacy of low levels of endogenous IFN-a, which
as produced locally as a result of virus infection. Re-
ently, Sanhadji and colleagues have also shown that
he transfer of Tat-inducible IFN genes protects human
ell lines against HIV-1 challenge in vitro as well as in
ivo after transplantation into SCID mice (Sanhadji et al.,
997). In our study, the finding that a high level of pro-
ection from both HIV-1 antigenemia and virus infection
as observed in mice transplanted with LTR-IFNA2 U937
ells compared to animals injected with control cells
mphasizes the concept that even very low levels of
ndogenously produced IFN are extremely effective in
nhibition of HIV-1 replication. In particular, the fact that
TR-IFNA2 U937 cells were capable of conferring a po-
ice infected with HIV-1 and treated with type I CIFN: comparison with
ZT and infected with HIV-1 (SF162) as described in the legend to Fig.
human CD41 and CD81 T cells recovered in the peritoneal washings
mice in each group. Values of two representative experiments of fourCID m
FN or A
ges of
re fourent protection against HIV infection when coinjected
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85ANTI-HIV-1 EFFECTS OF TYPE I IFN IN SCID MOUSE MODELSith parental virus permissive U937 cells strongly sug-
ests that the virus-induced IFN-a can represent a pow-
rful amplification system for inducing anti-HIV protec-
ion in bystander cells, probably by a combination of
utocrine and paracrine mechanisms at the infection
ite. These results appear to be consistent with results
y others showing that even very low levels of IFN-b
roduced by genetically modified human lymphocytes
an efficiently prevent HIV-1 infection and replication
Vieillard et al., 1995).
While the results obtained in the U937-SCID models
oint out the impressive efficacy of type I IFN in prevent-
ng HIV-1 infection of human cells under in vivo condi-
ions, the data in the hu-PBL-SCID mouse model pre-
ented in this article may also shed some light on the
ontroversial issue of the possible involvement of IFN-a
n the HIV-1-induced depletion of human CD4 T cells
Zagury et al., 1998). In fact, our results are in contrast
ith the hypothesis that CIFN can induce CD4 T cell
epletion and demonstrate that this cytokine can play a
ole in maintaining high levels of human CD4 T cells in
he virus-infected SCID mice reconstituted with human
BL. In some experiments (Fig. 6, experiment 2), we even
bserved an increase in the total number of human CD4
cells in CIFN-treated, HIV-1-infected hu-PBL-SCID mice
hen compared to the numbers detected in control un-
nfected mice reconstituted with human PBL. In all in-
tances, the protective effects of CIFN on HIV-1 infection
nd human CD4 T cell depletion were superior to those
ound in mice treated with optimal doses of AZT. Notably,
he finding that repeated high doses of CIFN in unin-
ected hu-PBL-SCID mice did not result in any suppres-
ion of the levels of human CD4 T cells indicates that,
ven in the absence of HIV-1 infection, CIFN does not
uppress the levels of CD4 T cells. Of interest, a strong
rotection from HIV-1-induced depletion of CD4 T cells
as also observed several days after discontinuation of
IFN treatment (Fig. 7). Notably, hu-PBL-SCID mice
reated with IFN showed a marked enhancement in the
erum human IgM levels, compared to the control
roups, which paralleled high levels of human CD4 T
ells (Fig. 7). Interestingly, CIFN-treated HIV-infected hu-
BL-SCID mice proved somehow resistant to a second
hallenge with HIV (data not shown). In this regard, it is
f interest to mention that human anti-HIV-1 antibodies
ere frequently detected in the sera of mice infected
ith HIV-1 and treated with CIFN. These observations
uggest that CIFN can efficiently restrict HIV-1 replica-
ion in hu-PBL-SCID mice not only by a direct induction of
n antiviral state in the human target cells, but also by
timulating anti-HIV human immune mechanisms. Al-
hough further studies are necessary to characterize the
ature of the IFN-induced human “immune” mechanisms
n HIV-1-infected hu-PBL-SCID mice, these results are
onsistent with an increasing number of reports indicat-ng that type I IFN can act as a powerful T cell adjuvant por the generation of a protective immune response to
umor growth and virus infections (for reviews, see Be-
ardelli and Gresser, 1996; Belardelli, 1995). In fact, while
he assumption that IFN-a can be an immunosuppres-
ive factor is based mostly on in vitro studies on the
FN-induced inhibition of T cell activation under certain
xperimental conditions (Zagury et al., 1998), some in
ivo studies have reported that this cytokine can en-
ance the in vivo proliferation of certain T cell subsets in
ice (Tough et al., 1996). Although the in vivo enhance-
ent of T cell proliferation by type I IFN in mice was
enerally observed for CD8 T cells (especially CD44hi)
Belardelli et al., 1998; Tough et al., 1996), an increase in
he proliferation of CD4 T cells was also detected in
nimals injected with cells expressing IFN-a (Belardelli
t al., 1998). Moreover, studies in human cell systems
ndicate that IFN-a can enhance the differentiation of T
ells toward a Th-1 type of immune response (Rogge et
l., 1997; Romagnani, 1992). In this regard, it is worth
entioning that recent studies on genetically modified
uman PBL expressing constitutive low levels of IFN-b
how that this cytokine not only can suppress HIV rep-
ication, but also can enhance an anti-HIV T cell reactiv-
ty, which is associated with the promotion of a Th-1 type
f immune response (Vieillard et al., 1997). Recent re-
ults also indicate that type I IFN is an important stimu-
ator of differentiation and activity of dendritic cells (Luft
t al., 1998; Paquette et al., 1998). All these data, together
ith the results of the present study, indicate that type I
FN can act as an important stimulator of T cell functions,
ather than a T cell suppressive factor, and suggest that
herapeutic interventions including IFN-a should be con-
idered for the prevention and therapy of HIV infection.
inally, our results emphasize the risk of extrapolating
esults obtained under in vitro conditions to clinical ap-
lications in patients and emphasize the importance of
sing animal models for the definition of selective strat-
gies to prevent HIV-1 infection and the virus-induced
isease.
MATERIALS AND METHODS
Animals. CB17 scid/scid female mice (Arlam, Nossan,
taly) were used at 4 weeks of age and were kept under
pecific pathogen-free conditions. SCID mice were
oused in microisolator cages and all food, water, and
edding were autoclaved prior to use.
Reagents. Monoclonal anti-mouse granulocyte anti-
odies (RB6-8C5 hybridoma) were prepared as previ-
usly described (Santini et al., 1998). Type I consensus
FN (Alton et al., 1983) is a synthetic IFN produced from
ecombinant DNA, whose sequence is based on a con-
ensus derived from the amino acid sequences of the
ost common types of human IFNa. CIFN had a specific
ctivity of 1 3 109 units/mg protein and was kindly
rovided by Amgen (Thousand Oaks, CA). IFN was ti-
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86 LAPENTA ET AL.rated on HeLa cells as described elsewhere (Zhang et
l., 1996). AZT (Sigma–Aldrich, Milwaukee, WI) was dis-
olved in prewarmed (40°C) PBS at a concentration of 9
g/ml and filter-sterilized. Mice were daily injected ip
ith 1 ml of a freshly prepared AZT solution [480 mg/kg/
ay (maximal tolerated dose)] or sc with 0.2 ml of CIFN
105 U/mouse).
Genetically modified U937 cells expressing the Tat-
nducible IFN-A2 gene and control transduced cells. The
rigin and characteristics of HIV-1-LTR-IFNA2 U937
clone ULTR5-14) cells have been described elsewhere
Su et al., 1995). Genetically modified U937 cells trans-
uced with the HIV-LTR control construct were used as
ontrols. Previous studies have shown that HIV-1 repli-
ation was restricted in vitro in the U937 cells trans-
uced with the Tat-transactivable IFN-A2 gene compared
o control cells (Poli et al., 1989). HIV-1-LTR-IFNA U937
ells produced low levels (80 U/ml) of IFN-A2; HIV-1
nfection consistently stimulated IFN production (Su et
l., 1995).
Growth of U937 cell tumors in SCID mice and in vivo
IV-1 infection (U937-SCID mouse model). The animal
tudies were performed in Biosafety Level 3 facility. Mice
ere injected sc in the shoulder with 20 3 106 uninfected
937 cells (Lapenta et al., 1997) resuspended in 0.2 ml
aline. The two major diameters of each tumor nodule
ere measured by caliper and the mean tumor diameter
f each tumor was calculated. To deplete animals of
ome residual reactivity, SCID mice were injected ip with
.2 ml (100 mg/mouse) of an anti-mouse granulocyte
Ab, 1 day before and 3 and 7 days after tumor cell
njection (Santini et al., 1998). The in vivo HIV infection of
937 SCID mice was performed using two different ap-
roaches: (i) simultaneous sc injection of 20 3 106 un-
nfected U937 cells with 106 TCID50 of cell-free HIV-1 IIIB;
ii) peritumoral injection of established (15 days postim-
lantation) uninfected U937 cells tumors with 106 TCID50
f cell-free HIV-1 IIIB.
Detection of viral infection in the U937-SCID model. At
acrifice, the HIV-infected chimeras were analyzed for
he virus replication at the tumor site and p24 antigen-
mia. In particular, the U937 cell tumors were excised,
arefully minced, and gently stirred for 30 min at 37°C in
rypsin–EDTA solution (ICN Pharmaceuticals, Amster-
am, The Netherlands) to obtain cell suspensions. Cell
uspensions underwent (a) HIV-1-DNA PCR as previ-
usly described (Lapenta et al., 1997; Rizza et al., 1996);
b) immunocytochemistry for the expression of HIV-p55/
18 (Lapenta et al., 1997); or (c) cocultivation with C8166
ells for syncytia formation. Sera of infected animals
ere tested for HIV p24 antigen by an antigen capture
nzyme-linked immunosorbant assay (Dupont, B-1130
russels, Belgium), for HIV-1 RNA copies by nucleid acid
equence-based amplification assay (NASBA HIV-1 RNA
T kit, Organon Teknika, Turnhout, Belgium), and also for
yncytia formation in C8166 cell cultures. pImmunocytochemistry. Cells were obtained by disag-
regation of tumors grown in infected SCID mice, at-
ached to L-poly-L-lysine-covered glass chamber slides
Labtek, Naperville, IL) and stained by immunocytochem-
stry for HIV-1 p55/p18 matrix protein (IgG1, clone 11H9,
rom Medical Research Council AIDS Reagent Project,
ondon, UK) using the alkaline phosphatase anti-alkaline
hosphatase (Dako, Denmark) method.
The hu-PBL-SCID mouse model. Hu-PBLs were ob-
ained from the peripheral blood of healthy donors. All
onors were screened for HIV-1 and hepatitis prior to
onation. The hu-PBLs were obtained by Ficoll-Paque
ensity gradient centrifugation. Twenty million cells were
esuspended in 0.5 ml RPMI 1640 medium and injected
p into the recipient mice. At different times after hu-PBL
njection, SCID mice were sacrificed and cells were
ollected from the peritoneal cavity, spleen, and lymph
odes. At each time, a two-step peritoneal lavage was
one. The first washing was performed with 1 ml of cold
PMI 1640 medium. The recovered volume was centri-
uged and the supernatant was stored at 220°C, while
he cells were pooled with those obtained with a second
-ml washing.
ELISA for human immunoglobulins. An ELISA system
as used to quantitate human IgG, IgM, and IgA in
eritoneal lavage and sera of the chimeras using a goat
nti-human F(ab)2 Ig antibody and peroxidase-coupled
oat anti-human IgG, IgM, and IgA (Cappel-Cooper Bio-
edical, West Chester, PA). All ELISAs were performed
n duplicate and laboratory standards were included on
ach plate. Peritoneal lavages and sera from nonrecon-
tituted SCID mice were used as negative controls of all
he ELISAs determinations. ELISA for detection of spe-
ific anti-HIV antibodies was performed as described in
etail elsewhere (Ausiello et al., 1994) using a specific
eptide (i.e., ERYLKDQQLLGIWGCSGKLIC) correspond-
ng to amino acids 591 to 611 of the gp41 HIV-1 protein.
ynthetic peptides were immobilized on Maxi Sorp
NUNC) microtiter plates by an overnight incubation at
°C with the peptide solution (100 ml/well; 2 mg/ml in
ater). Diluted mouse sera were added and incubated
or 90 min at room temperature. Finally, binding was
evealed by reading A450 values after a 15-min incubation
t room temperature with o-phenylenediamine as a sub-
trate. Values represent the mean adsorbance value of
ach individual serum tested in duplicate. The cut-off
alue was calculated as the mean adsorbance value of
ll the control sera. Sera showing A450 values higher than
his threshold were considered positive for anti-HIV an-
ibodies.
Flow cytometric analysis. Cells recovered from the
eritoneum of the hu-PBL-SCID mice were resuspended
n PBS and incubated with the appropriate fluorochrome-
onjugated mAbs for 30 min. Cells were then washed
ith 2% PBS, 0.1% FCS, sodium azide and fixed with 2.5%
araformaldehyde. Two-color flow-cytometry was per-
f
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87ANTI-HIV-1 EFFECTS OF TYPE I IFN IN SCID MOUSE MODELSormed on a FACSort cytometer (Becton Dickinson, San
ose, CA), and stained cells were analyzed using LYSIS II
Becton Dickinson) software. A total of 5000 events/sam-
le were collected. Cells were analyzed according to
orward- and side-scatter properties to gate the live cell
opulation, allowing for the exclusion of erythrocytes,
ead cells, and cell and tissue debris. The mAbs used
ere anti-human CD3, CD4, and CD8 (Becton Dickin-
on). None of the mAbs to human antigens showed
ross-reaction to murine epitopes.
Evaluation of HIV-1 infection in the hu-PBL-SCID
ouse model. For in vivo infection, 103 TCID50 of HIV-1
F162 were injected ip in hu-PBL-SCID mice 2 weeks
fter engraftment. The chimeras were sacrificed at 4–6
eeks after reconstitution and analyzed for HIV-1 infec-
ion by (i) DNA-PCR for viral specific sequences and for
etection of the HLA-DQa, as described elsewhere
Rizza et al., 1996) and (ii) p24-antigen detection in peri-
oneal lavage by ELISA (Dupont, B-1130). Sera of infected
nimals were tested for HIV-1 RNA copies by nucleid
cid sequence-based amplification assay (NASBA HIV-1
NA QT kit, Organon Teknika).
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